Regulatory-Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys.
- 1School of Pharmaceutical Engineering Shenyang Pharmaceutical University Shenyang 110016 Liaoning China syphu.edu.cn.
- 2Zhuhai Trinomab Pharmaceutical Co., Ltd. Zhuhai Guangdong China.
Abstract
Siltartoxatug-developed by Trinomab Pharmaceutical Co., Ltd., using its proprietary HitmAb® platform-is the first-in-class recombinant monoclonal antibody drug for urgent prophylaxis of tetanus approved by China National Medical Products Administration in February 2025, which addresses the critical unmet need to substitute blood-derived passive immunization preparations for prevention of tetanus. The nonclinical pharmacokinetic and immunogenicity study of siltartoxatug was designed and conducted in strict compliance with global regulatory guidelines for initiating the first-in-human clinical trials. Herein, we report the comprehensive findings from this study. Twenty-four naive cynomolgus monkeys (Macaca fascicularis) were randomly assigned to four groups each with 6 animals. Monkeys in Group 1 received intravenous infusion of siltartoxatug at 1 mg/kg. Monkeys in Groups 2, 3, and 4 received intramuscular injection of siltartoxatug at dose of either 1 mg/kg, 3 mg/kg, or 10 mg/kg. Blood samples were collected over 57 days post-administration, and serum drug concentrations and anti-drug antibody levels were determined with validated methods. Results showed that intramuscular administration of siltartoxatug exhibited favorable pharmacokinetic characteristics: primarily systemic distribution with high bioavailability (88.0% at 1 mg/kg) and low apparent volume of distribution (58.7-69.4 mL/kg), prolonged elimination half-life (11.7-12.4 days), short mean time to maximum concentration (1.2-2.7 days), and dose-dependent systemic exposure without significant sex differences. Additionally, minimal anti-drug antibody responses were observed. These findings underpinned greater predictability for its clinical translation and informed its first-in-human development.
Related
- Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025
- Association of gut microbiota and regulatory T cells with vaccine immunogenicity in HIV-exposed uninfected and HIV-unexposed infants: a longitudinal cohort study
- Moonlighting function of extracellular GPX4 on immunogenicity of ferroptosis
- Monoclonal Gammopathy in Autoimmune Diseases: Marker, Consequence, Pathogenetic Factor—Or Coincidence?
- Novel monoclonal antibodies for an activated protein C cleavage neoepitope of coagulation factor Va
BibTeX
@article{zhou2026regulatorydriven,
title = {{Regulatory-Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys.}},
author = {Xia Zhou and Fei Zhou and Zhenpeng Fu and Weijun Ye and Guo Li and Jason Li and Weihong Zheng and Hua-Xin Liao and Shaojie Wang and Xiaoyi Liu},
journal = {Advances in pharmacological and pharmaceutical sciences},
year = {2026},
month = oct,
doi = {10.1155/adpp/2804371},
url = {https://europepmc.org/article/MED/42898527},
note = {CC BY},
}
RIS
TY - JOUR
TI - Regulatory-Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys.
AU - Xia Zhou
AU - Fei Zhou
AU - Zhenpeng Fu
AU - Weijun Ye
AU - Guo Li
AU - Jason Li
AU - Weihong Zheng
AU - Hua-Xin Liao
AU - Shaojie Wang
AU - Xiaoyi Liu
PY - 2026
DA - 2026/10/18
JO - Advances in pharmacological and pharmaceutical sciences
DO - 10.1155/adpp/2804371
UR - https://europepmc.org/article/MED/42898527
AB - Siltartoxatug-developed by Trinomab Pharmaceutical Co., Ltd., using its proprietary HitmAb® platform-is the first-in-class recombinant monoclonal antibody drug for urgent prophylaxis of tetanus approved by China National Medical Products Administration in February 2025, which addresses the critical unmet need to substitute blood-derived passive immunization preparations for prevention of tetanus. The nonclinical pharmacokinetic and immunogenicity study of siltartoxatug was designed and conducted in strict compliance with global regulatory guidelines for initiating the first-in-human clinical trials. Herein, we report the comprehensive findings from this study. Twenty-four naive cynomolgus monkeys (Macaca fascicularis) were randomly assigned to four groups each with 6 animals. Monkeys in Group 1 received intravenous infusion of siltartoxatug at 1 mg/kg. Monkeys in Groups 2, 3, and 4 received intramuscular injection of siltartoxatug at dose of either 1 mg/kg, 3 mg/kg, or 10 mg/kg. Blood samples were collected over 57 days post-administration, and serum drug concentrations and anti-drug antibody levels were determined with validated methods. Results showed that intramuscular administration of siltartoxatug exhibited favorable pharmacokinetic characteristics: primarily systemic distribution with high bioavailability (88.0% at 1 mg/kg) and low apparent volume of distribution (58.7-69.4 mL/kg), prolonged elimination half-life (11.7-12.4 days), short mean time to maximum concentration (1.2-2.7 days), and dose-dependent systemic exposure without significant sex differences. Additionally, minimal anti-drug antibody responses were observed. These findings underpinned greater predictability for its clinical translation and informed its first-in-human development.
SN - 2633-4682
SN - 2633-4690
ER -